Your browser is no longer supported. Please, upgrade your browser.
argenx SE
Index- P/E- EPS (ttm)-1.73 Insider Own- Shs Outstand47.11M Perf Week10.21%
Market Cap14.65B Forward P/E- EPS next Y-14.09 Insider Trans- Shs Float47.03M Perf Month1.10%
Income- PEG- EPS next Q-3.04 Inst Own54.78% Short Float2.34% Perf Quarter21.10%
Sales- P/S- EPS this Y-171.80% Inst Trans- Short Ratio7.13 Perf Half Y21.79%
Book/sh11.95 P/B26.02 EPS next Y-10.80% ROA- Target Price304.30 Perf Year108.39%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range103.75 - 316.83 Perf YTD5.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.85% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low199.74% ATR10.46
Employees186 Current Ratio- Sales Q/Q16.10% Oper. Margin- RSI (14)61.66 Volatility3.72% 3.17%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.28 Prev Close315.29
ShortableYes LT Debt/Eq- EarningsOct 22 BMO Payout- Avg Volume154.63K Price310.98
Recom2.10 SMA206.45% SMA509.55% SMA20031.29% Volume198,693 Change-1.37%
Jan-04-21Downgrade Guggenheim Buy → Neutral
Aug-25-20Initiated Raymond James Outperform $257
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-29-20Initiated H.C. Wainwright Neutral $272
Feb-10-20Initiated BofA/Merrill Buy
Nov-05-19Initiated Credit Suisse Neutral $137
Oct-31-19Upgrade William Blair Mkt Perform → Outperform
Oct-22-19Initiated JP Morgan Overweight $167
Sep-27-19Initiated Wells Fargo Market Perform
Sep-16-19Resumed Cowen Outperform
Jun-28-19Initiated Robert W. Baird Outperform
Jan-18-19Resumed SunTrust Buy
Jan-04-19Initiated Morgan Stanley Overweight
Dec-17-18Initiated Goldman Buy
Dec-14-18Initiated Wolfe Research Outperform
Jun-29-18Initiated Nomura Buy $161
Apr-09-18Initiated SunTrust Buy $125
Jan-29-18Reiterated JMP Securities Mkt Outperform $74 → $87
Jan-08-21 01:00AM  
Jan-07-21 08:20AM  
Jan-06-21 04:01PM  
Jan-04-21 01:00AM  
Dec-19-20 09:32PM  
Dec-14-20 10:12AM  
Nov-23-20 01:00AM  
Nov-17-20 07:00AM  
Nov-09-20 01:00AM  
Nov-03-20 04:14PM  
Oct-22-20 12:30PM  
Oct-15-20 01:00AM  
Oct-06-20 08:24AM  
Oct-05-20 01:00AM  
Sep-16-20 04:53PM  
Sep-02-20 01:00AM  
Aug-04-20 01:00AM  
Jul-30-20 01:00AM  
Jul-29-20 01:46PM  
Jul-20-20 12:15PM  
Jul-01-20 09:24AM  
Jun-15-20 11:09AM  
Jun-01-20 04:00PM  
May-29-20 01:00AM  
May-28-20 12:15AM  
May-27-20 10:08AM  
May-26-20 04:01PM  
May-14-20 03:30PM  
May-12-20 09:52AM  
May-11-20 05:22AM  
May-08-20 11:46AM  
Mar-22-20 10:18PM  
Feb-27-20 08:09AM  
Feb-26-20 08:57AM  
Feb-09-20 03:01AM  
Jan-07-20 08:40AM  
Dec-29-19 09:40PM  
Dec-07-19 08:02AM  
Nov-22-19 03:22PM  
Nov-12-19 04:00PM  
Nov-10-19 02:52AM  
Nov-08-19 01:00AM  
Nov-06-19 10:45PM  
Oct-24-19 01:00AM  
Oct-14-19 10:14PM  
Sep-25-19 03:34AM  
Sep-03-19 01:00AM  
Aug-07-19 04:43AM  
Aug-06-19 01:00AM  
Aug-01-19 01:00AM  
Jul-25-19 01:00AM  
Jul-08-19 10:00AM  
Jun-20-19 01:35PM  
Jun-05-19 08:37AM  
May-22-19 07:34AM  
May-02-19 06:43PM  
Apr-25-19 02:38PM  
Apr-13-19 07:41AM  
Apr-03-19 05:35AM  
Feb-28-19 07:00AM  
Feb-04-19 01:00AM  
Jan-23-19 07:55AM  
Jan-22-19 01:52AM  
Dec-26-18 02:22PM  
Dec-03-18 04:09AM  
Nov-01-18 09:15AM  
Oct-25-18 02:04AM  
Oct-09-18 01:00AM  
Sep-21-18 04:01PM  
Sep-18-18 08:46PM  
Sep-17-18 04:21PM  
Sep-06-18 01:01AM  
Aug-29-18 01:01AM  
Aug-22-18 10:50AM  
Aug-09-18 04:06PM  
Aug-02-18 01:01AM  
Jul-26-18 01:06AM  
Jul-24-18 04:01PM  
Jul-17-18 01:01AM  
Jun-28-18 01:01AM  
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.A.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.